Cargando…

A new approach to tissue engineering of vascularized skeletal muscle

Tissue Engineering of skeletal muscle tissue still remains a major challenge. Every neo-tissue construct of clinically relevant dimensions is highly dependent on an intrinsic vascularisation overcoming the limitations of diffusion conditioned survival. Approaches incorporating the arteriovenous-loop...

Descripción completa

Detalles Bibliográficos
Autores principales: Bach, A D, Arkudas, A, Tjiawi, J, Polykandriotis, E, Kneser, U, Horch, R E, Beier, J P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3933153/
https://www.ncbi.nlm.nih.gov/pubmed/16989731
http://dx.doi.org/10.1111/j.1582-4934.2006.tb00431.x
_version_ 1782304888035737600
author Bach, A D
Arkudas, A
Tjiawi, J
Polykandriotis, E
Kneser, U
Horch, R E
Beier, J P
author_facet Bach, A D
Arkudas, A
Tjiawi, J
Polykandriotis, E
Kneser, U
Horch, R E
Beier, J P
author_sort Bach, A D
collection PubMed
description Tissue Engineering of skeletal muscle tissue still remains a major challenge. Every neo-tissue construct of clinically relevant dimensions is highly dependent on an intrinsic vascularisation overcoming the limitations of diffusion conditioned survival. Approaches incorporating the arteriovenous-loop model might bring further advances to the generation of vascularised skeletal muscle tissue. In this study 12 syngeneic rats received transplantation of carboxy-fluorescine diacetate-succinimidyl ester (CFDA)-labelled, expanded primary myoblasts into a previously vascularised fibrin matrix, containing a microsurgically created AV loop. As control cells were injected into fibrin-matrices without AV-loops. Intra-arterial ink injection followed by explantation was performed 2, 4 and 8 weeks after cell implantation. Specimens were evaluated for CFDA, MyoD and DAPI staining, as well as for mRNA expression of muscle specific genes. Results showed enhanced fibrin resorption in dependence of AV loop presence. Transplanted myoblasts could be detected in the AV loop group even after 8 weeks by CFDA-fluorescence, still showing positive MyoD staining. RT-PCR revealed gene expression of MEF-2 and desmin after 4 weeks on the AV loop side, whereas expression analysis of myogenin and MHC(embryo) was negative. So far myoblast injection in the microsurgical rat AV loop model enhances survival of the cells, keeping their myogenic phenotype, within pre-vascularised fibrin matrices. Probably due to the lack of potent myogenic stimuli and additionally the rapid resorption of the fibrin matrix, no formation of skeletal muscle-like tissue could be observed. Thus further studies focussing on long term stability of the matrix and the incorporation of neural stimuli will be necessary for generation of vascularised skeletal muscle tissue.
format Online
Article
Text
id pubmed-3933153
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher John Wiley & Sons, Ltd
record_format MEDLINE/PubMed
spelling pubmed-39331532015-07-06 A new approach to tissue engineering of vascularized skeletal muscle Bach, A D Arkudas, A Tjiawi, J Polykandriotis, E Kneser, U Horch, R E Beier, J P J Cell Mol Med Phenomenin Review Series Tissue Engineering of skeletal muscle tissue still remains a major challenge. Every neo-tissue construct of clinically relevant dimensions is highly dependent on an intrinsic vascularisation overcoming the limitations of diffusion conditioned survival. Approaches incorporating the arteriovenous-loop model might bring further advances to the generation of vascularised skeletal muscle tissue. In this study 12 syngeneic rats received transplantation of carboxy-fluorescine diacetate-succinimidyl ester (CFDA)-labelled, expanded primary myoblasts into a previously vascularised fibrin matrix, containing a microsurgically created AV loop. As control cells were injected into fibrin-matrices without AV-loops. Intra-arterial ink injection followed by explantation was performed 2, 4 and 8 weeks after cell implantation. Specimens were evaluated for CFDA, MyoD and DAPI staining, as well as for mRNA expression of muscle specific genes. Results showed enhanced fibrin resorption in dependence of AV loop presence. Transplanted myoblasts could be detected in the AV loop group even after 8 weeks by CFDA-fluorescence, still showing positive MyoD staining. RT-PCR revealed gene expression of MEF-2 and desmin after 4 weeks on the AV loop side, whereas expression analysis of myogenin and MHC(embryo) was negative. So far myoblast injection in the microsurgical rat AV loop model enhances survival of the cells, keeping their myogenic phenotype, within pre-vascularised fibrin matrices. Probably due to the lack of potent myogenic stimuli and additionally the rapid resorption of the fibrin matrix, no formation of skeletal muscle-like tissue could be observed. Thus further studies focussing on long term stability of the matrix and the incorporation of neural stimuli will be necessary for generation of vascularised skeletal muscle tissue. John Wiley & Sons, Ltd 2006-07 2007-05-01 /pmc/articles/PMC3933153/ /pubmed/16989731 http://dx.doi.org/10.1111/j.1582-4934.2006.tb00431.x Text en
spellingShingle Phenomenin Review Series
Bach, A D
Arkudas, A
Tjiawi, J
Polykandriotis, E
Kneser, U
Horch, R E
Beier, J P
A new approach to tissue engineering of vascularized skeletal muscle
title A new approach to tissue engineering of vascularized skeletal muscle
title_full A new approach to tissue engineering of vascularized skeletal muscle
title_fullStr A new approach to tissue engineering of vascularized skeletal muscle
title_full_unstemmed A new approach to tissue engineering of vascularized skeletal muscle
title_short A new approach to tissue engineering of vascularized skeletal muscle
title_sort new approach to tissue engineering of vascularized skeletal muscle
topic Phenomenin Review Series
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3933153/
https://www.ncbi.nlm.nih.gov/pubmed/16989731
http://dx.doi.org/10.1111/j.1582-4934.2006.tb00431.x
work_keys_str_mv AT bachad anewapproachtotissueengineeringofvascularizedskeletalmuscle
AT arkudasa anewapproachtotissueengineeringofvascularizedskeletalmuscle
AT tjiawij anewapproachtotissueengineeringofvascularizedskeletalmuscle
AT polykandriotise anewapproachtotissueengineeringofvascularizedskeletalmuscle
AT kneseru anewapproachtotissueengineeringofvascularizedskeletalmuscle
AT horchre anewapproachtotissueengineeringofvascularizedskeletalmuscle
AT beierjp anewapproachtotissueengineeringofvascularizedskeletalmuscle
AT bachad newapproachtotissueengineeringofvascularizedskeletalmuscle
AT arkudasa newapproachtotissueengineeringofvascularizedskeletalmuscle
AT tjiawij newapproachtotissueengineeringofvascularizedskeletalmuscle
AT polykandriotise newapproachtotissueengineeringofvascularizedskeletalmuscle
AT kneseru newapproachtotissueengineeringofvascularizedskeletalmuscle
AT horchre newapproachtotissueengineeringofvascularizedskeletalmuscle
AT beierjp newapproachtotissueengineeringofvascularizedskeletalmuscle